Manufacturers announce development of anti-GM-CSF monoclonal antibody to prevent and treat acute respiratory distress syndrome in patients with covid-19

Manufacturers aim to rapidly advance the clinical development of gimsilumab for this indication. GM-CSF is a pro-inflammatory cytokine found to be up-regulated in the serum of COVID-19 patients according to recent data from patients in China.


Biospace Inc.